Asset profile
AADvac1
Vaccine
Evidence outlook · lead readout
ADAMANT (NCT02579252) · Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
ADAMANT (NCT02579252): The study was randomized, quadruple-blind, placebo-controlled, and included 208 participants, with safety as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 32 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AADvac1: this drug | Phase 2 | Vaccine | Tau (monoclonal antibody) | ||
| NIO752 | Phase 3 | RNA / oligonucleotide | Tau (monoclonal antibody) | ||
| Etalanetug | Phase 2/3 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| Bepranemab | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| BMS-986446 | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| ACI-35.030 | Phase 1/2 | Vaccine | Tau (monoclonal antibody) | ||
| VY7523 | Phase 1/2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| APNmAb005 | Phase 1 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (2)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.